CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
SUPPRESSTEM focuses on developing novel antibody-based drugs to target cancer stem cells in colorectal cancer. The project aims to improve drug screening methods using patient-derived organoids to enhance treatment effectiveness.
Colorectal cancer (CRC) was diagnosed in 1.23 million people worldwide (EU 333,000) in 2008 and 608,000 (EU 148,000) died of the disease.
While some new treatments have been advanced in CRC many have failed clinical testing; metastatic CRC is still largely incurable.In CRC, Cancer Stem Cells (CSC) are responsible for tumour progression and resistant to standard chemotherapies.
The Wnt signal transduction cascade controls normal colon physiology but also CSC maintenance.
Deregulation of Wnt and o…
MERUS BV
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, LEIDEN
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Spain, Barcelona
Type: Research institute
Activity type: Research Organisations
SME: No
United Kingdom, SAFFRON WALDEN
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
